Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.